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pathological examination of resected specimens [4]. ThisIntroduction
creates uncertainty and controversy about the compara-
tive eBcacy of diCerent treatments and expected out-The medical management of patients with prostate or
testis cancer is based on knowledge of the biological comes for patients. Standardization of staging procedures
after radical prostatectomy (RP) and clearly defining thebehaviour of these malignancies, as well as factors such
as the patient’s age and general medical condition. extraprostatic extension and positive surgical margins
will result in significant improvements in staging.Depending on the expected prognosis, a patient may be
treated with curative intent, at times enduring consider- Additional data to enhance the accuracy of staging and
prediction of clinical outcome for individual patientsable morbidity from the treatment. In other cases, a
palliative approach, based on quality-of-life issues, may may include; systematic biopsies to predict preoperative
tumour volume and a volume-based prognostic index,be the treatment of first choice. It is a challenging task
to choose the optimal therapy for an individual patient linking cancer volume with extraprostatic extension,
seminal vesicle invasion and lymph node metastases [5].because of diBculties in predicting precisely the course
of the malignant process in each patient. Studies on A multiple prognostic index [6], including variables such
as serum PSA, tumour volume, tumour grade, tumourtissue-related prognostic factors form an extensive part
of the contemporary oncological literature. Such studies localization and DNA content, may have more predictive
power than conventional staging methods alone.oCer an insight to the molecular pathogenesis of malig-
nancies, potentially improving the power to predict the
clinical course and thus assisting in clinical decision-
Grade
making. In this review, we discuss the clinical use of
tissue-related prognostic factors in prostate and testis The Gleason grading system is currently the most widely
used system for grading prostate cancer and is a powerfulcancer and assess the published literature on experimen-
tal prognostic markers. variable in the management of patients with this con-
dition. It takes into account the histological tumour
heterogeneity of prostate cancer. This feature andProstate cancer
tumour multifocality can result in significant sampling
errors when grading is established from needle-coreProstate cancer is the commonest cancer in western
men and is second only to lung cancer as a cause of biopsies [7,8]. Furthermore, the prognostic power of
grade is greatest in tumours with the lowest (2–4) orcancer death [1,2]. As the overall lifetime probability
of developing clinically evident prostate cancer is much highest (8–10) scores. However, most tumours have an
intermediate score (5–7) and show strikingly hetero-lower than the prevalence at autopsy by the age of
80 years (16% vs 80%), most men die with rather than geneous biological aggressiveness. The Gleason score
cannot discriminate the indolent from the more aggress-from prostate cancer. However, it is clinically important
to distinguish the potentially lethal from the relatively ive cancers. Also, inter- and intra-observer variability
handicap the use of the Gleason score as a prognosticatorindolent tumours. The use of prognostic markers may
be crucial to identify the subgroup of patients with in patients with prostate cancer.
aggressive prostate cancer. We will discuss both clinically
applied markers and experimental markers.
PSA
Since its discovery in 1971 and its purification from
Stage
seminal plasma and the prostate in 1979, PSA has been
widely used as a tumour marker for screening, diagnosisThe TNM system is the one most commonly used for
clinical and pathological staging of prostate cancer [3]; and monitoring of prostate cancer [9]. Although the
name suggests otherwise, PSA is not produced exclus-it involves determining the anatomical extent of the
tumour. Currently, it is associated with problems of ively by the prostate but has been detected in urine, the
periurethral glands, peri-anal glands, saliva, amnioticunderstaging and sometimes overstaging, as shown by
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fluid, milk of lactating women and serum of some women be inferior to the PSA RT-PCR assay [24] but this assay
requires further study.with renal cancer. PSA is not strictly organ-specific, nor
is it disease-specific; elevated PSA levels can be found in
a small proportion of normal men and in many men
Epithelial cadherins
with BPH and prostatitis. Although PSA is not a perfect
marker, many publications have confirmed the value of Epithelial cadherin (E-cadherin) is a calcium-dependent
cell adhesion molecule that plays an important role inserum PSA level as a prostate cancer marker and as a
surrogate endpoint for studies of locally confined prostate maintaining the epithelial phenotype. Decreased
expression of E-cadherin has been detected in severalcancer [10]. The role of PSA as a predictor of outcome
in prostate cancer has been proposed by several investi- carcinomas, and implies disordered intercellular attach-
ment and increased risk of invasion and metastasis [25].gators [11]. Tissue PSA has been the subject of fewer
reports, although its prognostic value has been studied The role of E-cadherin in prostate cancer was reported
in studies of the Dunning rat prostate cancer, in whichin biopsy specimens [12–14] and TUR specimens [15]
with T1b prostate cancer, indicating that PSA immuno- E-cadherin was expressed by normal rat prostate tissue
and noninvasive tumours but was undetectable in invas-histochemistry could predict clinical outcome. Most stud-
ies have reported that tissue and serum PSA levels are ive rat prostate cancer sub-lines [26]. In human pros-
tate cancer an inverse correlation between E-cadherincorrelated. As serum PSA is considerably easier to obtain,
its value as a prognostic marker is greater than tissue expression and grade, stage and overall survival has
been reported, suggesting a role for E-cadherin as aPSA. However, undiCerentiated androgen-unresponsive
prostate cancer cells are unable to produce PSA, possibly prognosticator in prostate cancer [25]. More studies are
needed to confirm these findings and to determine theexplaining the lack of PSA increase in a proportion of
patients with hormone-refractory disease. Novel appli- precise clinical importance of E-cadherin.
cations of PSA, such as PSA density, PSA slope, PSA
doubling time and free PSA have been derived and
DNA content (ploidy)
have, to a certain extent, improved the sensitivity and
specificity of PSA testing [16]. Tumour DNA content has been the subject of numerous
studies of prostate cancer (reviewed by Adolfsson [27]).Recently, research has focused on detecting circulating
PSA-producing cells using RT-PCR to detect PSA-mRNA. Many of these studies have suggested that the DNA
aneuploidy of RP specimens and needle biopsies corre-In one study, the presence of circulating PSA-mRNA
was of independent prognostic value in predicting PSA lates with progression, metastasis and poor prognosis,
although conflicting data have been presented. Theprogression after RP [17]. Positive results should be
interpreted cautiously as the PSA gene is not uniquely clinical applicability of tumour ploidy measurements
has been discussed in reports by the WHO [28] and theexpressed in prostate cells and the clinical significance
of single circulating tumour cells is unknown. College of American Pathologists [29]. The former
group advised the use of ploidy assessments for T2 and
T3 tumours, whereas the latter group concluded that
Prostate-specific membrane antigen (PSMA)
DNA ploidy may be useful in patients with stage T3
or pN+ tumours who are subsequently treated withPSMA is a relatively new marker for prostate cancer
[18] and is expressed by most intra-epithelial neoplasms adjuvant hormonal therapy. DNA ploidy has potential
as a prognostic marker, but its clinical role remains aas well as primary and metastatic prostate cancer speci-
mens. PSMA is also expressed at detectable levels in matter of debate. Phase-III clinical trials are needed to
clarify this issue and to prove that ploidy status providessmall intestine, brain and salivary gland [19]. At present,
the role of PSMA as a prognostic marker for prostate information beyond stage and grade. In addition, tech-
nical issues, involving DNA determination by imagecancer is inconclusive. The expression of PSMA was
high in poorly diCerentiated and metastatic cancer speci- analysis, need to be resolved to allow such studies
to proceed.mens, but did not correlate with nodal status, seminal
vesicle invasion or extraprostatic extension. The ratio of
PSMA and PSMA∞, an alternatively spliced variant of
Nuclear morphometry
PSMA mRNA, may be a useful index for assessing
prostate cancer progression [20]. Studies of serum PSMA Measurement of nuclear roundness, size, form and tex-
ture of nuclei may have prognostic value in patientsreported that serum PSMA levels may serve as a prognos-
tic marker for prostate cancer [21–23]. PSMA RT-PCR with prostate cancer [30]. However, diBculties with
image analysis techniques, tissue handling and reproduc-assays have been developed to detect circulating PSMA-
producing cells in the blood; the sensitivity appears to ibility of results remain a major concern and have
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prevented further evaluation of nuclear morphometry as
Apoptosis
a prognosticator in prostate cancer patients.
Apoptosis, or programmed cell death, may be an import-
ant factor in the response to therapy of prostate cancer
12-lipoxygenase
and for prognosis. The bcl-2 protein is able to block the
apoptotic pathway [39]. In normal prostate tissue bcl-212-lipoxygenase (12-LOX) is responsible for the pro-
duction of 12(S)-hydroxy-eicosatetraenoic acid [12(S)- is expressed in the basal cell layer of glands, but not in
the secretory cells. In hormone-refractory prostate cancerHETE] which plays a role in invasion and metastasis of
cancer [31]. 12-LOX may serve as a correlative marker the expression of bcl-2 is markedly increased [40] suggest-
ing that elevated levels of this protein may provide prostatefor prostate cancer with an aggressive phenotype
and poor prognosis, as shown by RT-PCR and in situ cancer cells with the ability to survive in an environment
with no androgens. Transfection of bcl-2 into the hor-hybrid ization in a study comparing expression of
12-LOX in prostate cancer tissues of diCerent stages mone-dependent prostate cancer cell line LNCaP enabled
these cells to survive in an androgen-depleted milieu [41].[31].
In one study, bcl-2 had prognostic value using univariate
analysis when examining RP samples [42] and in a
P53 tumour-suppressor gene
further study was an independent prognosticator for time
to PSA progression [43]. As apoptosis involves manyWild-type p53 protein is a suppressor of cell growth and
transformation, causing inhibition of cell proliferation other proteins (such as p53, bax and bcl-X) and is related
to proliferation, prognostic marker studies should beby G1 arrest and, under certain circumstances, apoptosis.
Mutation on the p53 gene, which is located on the short conducted combining these factors.
arm of chromosome 17, is the most common alteration
in cancers. Loss of wild-type p53 function can lead to
Neuroendocrine diCerentiation
deregulation of the cell cycle and DNA replication,
defective DNA repair, and selective growth advantage, Neuroendocrine cells are components of prostatic ducts
and acini, as well as prostate cancer with neuroendocrineresulting in tumour formation and progression [32]. The
role of p53 and its prognostic value in human prostate diCerentiation, which may show resistance to hormonal
therapy [44]. However, most studies report no significantcancer remains unclear. A correlation between mutation
of the p53 gene and tumour progression has been prognostic relevance [45].
reported in several studies, with mutations occurring as
a late event in the development of prostate cancer
Other prognostic markers
[33,34]. However, other studies did not confirm this
correlation [35] and suggested that p53 abnormalities The number of studies published on prognostic markers
for prostate cancer is rapidly increasing. Many newmay be an early event in prostate cancer progression
[36]. Larger well-defined groups of patients must be experimental markers have been described, and their
clinical importance and applicability as prognosticatorsstudied to assess definitively the prognostic value of
p53 in prostate cancer. Standardization of a method of remain to be determined. These markers include micro-
vessel density (angioneogenesis) [46], TGFb1 [47] oligo-assessing p53 also remains an issue.
saccharide sialyl Lewis-X [48], CD44 [49] and onco-
antigen 519 [50].
Tumour proliferative activity
Prostate cancers generally have low levels of prolifer- Conclusion
ation. DiCerent techniques can be used to assess cellular
proliferation, including flow cytometry, determination of A vast number of publications have appeared on prog-
nostic markers for prostate cancer, discussing both clini-the S-phase fraction, bromodeoxyuridine labelling and
immunostaining for proliferating cell nuclear antigen cally useful and experimental markers [51,52]. Clinical
and pathological stage (TNM classification), histological(PCNA) and Ki-67. The potential prognostic value of
proliferation has been examined by several groups, with grade (Gleason score) and serum PSA, with its molecular
variants, are the most powerful prognostic factors inconflicting results. Some have reported a positive corre-
lation with grade and stage [37], while others have not prostate cancer. However, at present, there are no
tumour markers that can reliably predict the clinical[38]. Heterogeneity within a tumour poses problems in
interpreting the results. At present, inconsistent results course of prostate cancer for an individual patient.
Further eCorts are needed in the search for the idealhamper the clinical application of proliferative activity
as a prognosticator. prognostic marker for prostate cancer.
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tumours, or combinations of these tumours [59]. PatientsTesticular cancer
with pure seminoma do not have elevated AFP levels.
On complete tumour excision, serum AFP levels mayTesticular cancer has a relatively good prognosis, even
in an advanced stages. Cure rates for disseminated germ return to normal in #1 month, depending on the peak
serum concentration and AFP half-life.cell tumours of 90% have been reported in patients
undergoing cisplatin-based chemotherapy [53]. Improve- Another marker, hCG, is normally produced by syncy-
tiotrophoblasts of the placenta. Normal males havements in staging methods, surgical techniques and radio-
therapy have also contributed to this favourable serum levels of the beta subunit (b-hCG) of <5 mIU/mL,
but b-hCG levels are elevated in 40–60% of patientsprognosis.
Nevertheless, the optimal management of patients with testicular cancer. b-hCG levels are high in all cases
of choriocarcinoma, 80% of cases of embryonal cellwith locally confined disease remains to be defined.
Morbidity and toxicity from treatment regimens must be carcinoma and 10–25% of cases of pure seminoma [59].
Levels return to normal values normally about a weekreduced, while maintaining high cure rates. Further-
more, it is important to identify those patients who are after radical tumour excision, depending on the peak
serum concentration and the half-life of b-hCG. Elevatedat risk of metastatic relapse. If the risk of metastasis could
be determined using prognostic factors, an individually levels of AFP and b-hCG are not specific for testicular
cancer and may occur with benign liver disease, anddesigned therapy could be oCered to the patient.
In patients with advanced nonseminomatous testicu- with lung, gastric, pancreatic, hepatocellular cancer
(AFP) and breast, bladder, pancreatic, gastric, hepatocel-lar cancer complete remission rates are still low in some
subgroups. Despite considerable progress since the lular and lung cancer (b-hCG) [58].
The enzyme LDH is responsible for lactic acid oxidationintroduction of cisplatin-based chemotherapy, ~20% of
patients presenting with metastases die from their disease in muscle, liver and kidneys. The level of isoenzyme 1 is
elevated in most patients with advanced testicular can-[54]. In this group, the goal of investigational trials is
to improve the proportion of complete remissions while cers and particularly in those with large-volume
tumours [58].accepting concurrent toxicity. The application of prog-
nostic factors might help to define a more individual Recently, international consensus on the stratification
of patients with testicular cancer has been reached bytreatment schedule for these patients, resulting in
increased cure rates and diminished side-eCects of the International Germ Cell Cancer Collaborative Group
(IGCCCG), based on data from multiple clinical trialstherapy.
Among urological malignancies, testicular cancer in Europe, North America and Australia (reviewed by
McCaCrey [54]). This group found that pretreatmenttakes a special place because clinical decision-making is
largely based on the application of prognostic factors. To levels of AFP, hCG and LDH, the site of the primary
tumour and the presence of nonpulmonary visceralassess the risk for metastatic testicular cancer the most
important prognostic features are the extent of the metastases were independent prognosticators for sur-
vival. Using this classification, patients with nonsemino-disease and serum determination of tumour markers.
matous germ cell tumours (NSGCTs) can be stratified
into three groups based on response to chemotherapy
Histological prognostic factors
(Table 1). Patients with seminoma patients could be
divided in two risk groups; one with ‘good risk’, with noHistological prognostic factors include the percentage of
embryonal carcinoma within the primary tumour [55], evidence of nonpulmonary metastases, and an intermedi-
ate risk group with evidence of nonpulmonary metast-and vascular invasion, i.e. the infiltration of testicular
veins by the tumour. In a recent study by Lewis et al. ases. This consensus has resulted in a new staging
system for testis cancer, that incorporates both serum[56], the presence of embryonal carcinoma within the
primary tumour, in addition to vascular invasion, markers and anatomical features, which is clinically
relevant to the selection of patients for optimal treatment.appeared to be an independent prognostic factor for
tumour progression, and the prognostic relevance was
prospectively confirmed [57].
Experimental prognostic factors
The prognostic value of DNA index, S-phase fraction and
Serum tumour markers
proliferation index in NSGCTs has been reported [60],
but results are conflicting; in multivariate analysis theseAFP, a foetal serum-binding protein, is normally found
in minimal amounts (<100 ng/L) after the first year of factors were not superior to histological prognostic fac-
tors such as vascular invasion and the presence oflife [58]. It is elevated in 50–70% of patients with
testicular cancers, including yolk sac and embryonal embryonal carcinoma cells.
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Table 1 International Germ Cell Cancer
Collaborative Group; nonseminomatous
germ cell tumour risk groups
Evidence of
Risk LDH hCG AFP nonpulmonary
group ×normal (IU/mL) (mg/mL) metastases
Good <1.5 <5 <1 No
Intermediate 1.5–10 5–50 1–10 No
Poor >10 >50 >10 Yes
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disease in clinical stage I nonseminomatous testicular germ (d) E-cadherin expression is inversely correlated with
cell tumors. J Urol 1993; 150: 879–83 grade, stage and overall survival in prostate cancer
61 Atkin NB, Baker MC. Specific chromosome change, i(12p),
4. Which statement is correct?in testicular tumours? Lancet 1982; 2: 1349
62 Bosl GJ, Dmitrovsky E, Reuter VE et al. Isochromosome of (a) DNA ploidy is a good prognosticator in stage T1
the short arm of chromosome 12: clinically useful markers (b) the value of p53 in prostate cancer as a prognostic
for male germ cell tumors. J Natl Cancer Inst 1989; factor is still unclear
81: 1874–8 (c) proliferative activity is established as a valuable
63 Rodriguez E, Mathew S, Reuter V, Ilson DH, Bosl GJ, prognosticator in prostate cancer
Chaganti RS. Cytogenetic analysis of 124 prospectively (d) neuroendocrine diCerentiation is inversely corre-
ascertained male germ cell tumors. Cancer Res 1992;
lated to prognosis in prostate cancer52: 2285–91
64 Strohmeyer T, Peter S, Hartmann M et al. Expression of 5. Which statement is correct?
the hst-1 and c-kit protooncogenes in human testicular (a) prognostic markers can distinguish between
germ cell tumors. Cancer Res 1991; 51: 1811–6
aggressive and indolent tumours
(b) more men die with prostate cancer rather than
Authors from prostate cancer
(c) a DRE is more accurate in diagnosing prostateJ.P. van Brussel, M.D., President in Urology.
G.H.J. Mickisch, M.D., PhD, Professor of Urology. cancer in stage T1c than is the PSA level
Correspondence: Academic Hospital Rotterdam, H1095, Dr (d) PSA values of <10 ng/mL excludes the appearance
Molenwaterplein 40, NL 3015 GD Rotterdam, The Netherlands. of bone metastasis
E-mail: Mickisch@urol.azr.nL
6. Which statement is correct?
(a) prostate specific membrane antigen (PSMA) is only
MCQs
expressed by prostatic intraepithelial neoplasia, primary
or metastatic prostate cancer1. Which statement is correct?
(b) hormone-independent growth of prostate cancer(a) tissue markers have found widespread acceptance
in clinical decision making can be achieved by the expression of bcl-2
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(c) expression of CD44 splice variants may be inversely 9. Which statement is correct?
(a) an important area for prognostic factors in testicularcorrelated with the prognosis of patients with prostate
cancer cancer is to identify patients with a high risk for meta-
static relapse(d) determination of proliferative activity has clinical
value as a prognosticator for prostate cancer (b) to date, prognostic factors in testicular cancer had
little impact on clinical decision-making compared with
7. Which statement is correct?
other urological malignancies
(a) the main goal of current treatment strategies in
(c) AFP levels may provide a valuable indication of the
stage I and II testicular cancer is to attain higher
management of patients with seminoma
cure rates
(d) hCG levels are increased in half of patients with
(b) the side-eCects of therapy in low-stage testicular
choriocarcinoma, with a subsequent impact on their
cancer are minor, if any
prognosis
(c) primary testicular cancer is refractory to many
forms of chemotherapy
10. Which statement is correct?
(d) patients with seminoma with lung metastasis may
(a) pre-treatment levels of AFP and hCG are not inde-
belong to a good-risk group
pendent prognosticators for survival in patients with
NSGCTs8. Which statement is correct?
(a) elevated levels of AFP and hCG are specific for (b) the percentage of embryonal carcinoma within the
primary testicular cancer is inversely correlated with thetesticular cancer
(b) large-volume testicular cancer most commonly prognosis
(c) an increased frequency of chromosomal alterationsinduces higher levels of LDH isoenzyme 1
(c) amplification of the HST-1 proto-oncogene has been is established as a prognosticator in NSGCTs
(d) levels of AFP and bhCG after treatment are mostreported to correlate with low-stage testicular cancer
(d) elevation of hCG worsens the prognosis of useful in clinical-decision making
seminoma
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